Fintel reports that on April 28, 2025, HSBC downgraded their outlook for Eli Lilly and (NYSE:LLY) from Buy to Reduce. Analyst ...

HSBC analyst warns of a downside in Eli Lilly stock to $700. Rajesh Kumar cited 'valuation' as his number 1 concern.

The firm said the risk-reward for Eli Lilly (NYSE:LLY) is "not attractive," especially given uncertainties surrounding the future growth of its obesity drug franchise. HSBC noted, "We are not ...

Eli Lilly And Co (NYSE:LLY) stock is 1.6% lower to trade at $870.31 at last check, after a rare double downgrade from HSBC to ...

The firm said the risk-reward for Eli Lilly (NYSE:LLY) is "not attractive," especially given uncertainties surrounding the future growth of its obesity drug franchise. HSBC (LON:HSBA) noted, "We are ...

Fintel reports that on April 28, 2025, HSBC downgraded their outlook for Eli Lilly and (WBAG:LLYC) from Buy to Reduce. There are 5,524 funds or institutions reporting positions in Eli Lilly and.

Eli Lilly (LLY), on the other hand, saw a double downgrade from HSBC analysts. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.

Eli Lilly (LLY) shares dip after HSBC double downgraded the stock to reduce — a sell-equivalent rating — from buy, saying the drugmaker’s risk-reward “is not attractive.” - Peloton ...